BioArctic Logo

BioArctic

Biopharmaceutical firm developing antibody therapies for neurodegenerative diseases.

BIOA | ST

Overview

Corporate Details

ISIN(s):
SE0010323303 (+1 more)
LEI:
549300Y0OI2WVUNHLC33
Country:
Sweden
Address:
Warfvinges väg 35, 112 51 Stockholm

Description

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2026-01-06 12:00
Ansökan om marknadsgodkännande för subkutan behandling med Leqembi® inlämnad oc…
Swedish PDF 198.6 KB
2026-01-06 12:00
BLA for subcutaneous formulation of Leqembi® accepted in China
English PDF 172.7 KB
2025-11-28 18:30
Number of shares and votes in BioArctic AB (publ) as of November 28, 2025
English PDF 186.5 KB
2025-11-28 18:30
Antal aktier och röster i BioArctic AB (publ) per den 28 november 2025
Swedish PDF 205.9 KB
2025-11-28 06:30
Ansökan om marknadsgodkännande för subkutan behandling med Leqembi[®] inlämnad …
Swedish PDF 222.5 KB
2025-11-28 06:30
New drug application for subcutaneous formulation of Leqembi[®] submitted in Ja…
English PDF 201.6 KB
2025-11-25 13:37
Eisai slutför stegvis ansökan för subkutan initieringsbehandling med Leqembi® I…
Swedish PDF 220.9 KB
2025-11-25 13:37
Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irm…
English PDF 206.5 KB
2025-11-13 08:00 Swedish PDF 1.8 MB
2025-11-13 08:00 English PDF 1.7 MB
2025-10-30 11:00
Försäljningen av Leqembi® uppgick till 18 miljarder yen under det tredje kvarta…
Swedish PDF 216.8 KB
2025-10-30 11:00
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
English PDF 198.1 KB
2025-10-17 15:00
BioArctic presents Nomination Committee
English PDF 226.6 KB
2025-10-17 15:00
BioArctic presenterar valberedningen
Swedish PDF 225.6 KB
2025-09-29 08:15
Kina godkänner intravenös underhållsbehandling med Leqembi®
Swedish PDF 235.6 KB

Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioArctic

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioArctic via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-07-27 Cecilia Edström Other Buy 3,500 1,013,204.85 SEK
2023-06-02 Sten Mikael Moge Other Sell 500 164,400.00 SEK
2023-05-31 Oskar Bosson Other Sell 2,500 785,250.00 SEK
2023-05-30 Oskar Bosson Other Sell 2,950 924,235.00 SEK
2023-05-21 Johanna Margareta Fälting Other Other 7,500 627,000.00 SEK
2023-05-19 Sten Mikael Moge Other Sell 2,000 619,866.00 SEK
2023-05-18 Oskar Bosson Other Other 12,000 722,280.00 SEK
2023-05-17 Christer Möller Other Other 3,000 250,800.00 SEK
2023-05-16 Sten Mikael Moge Other Other 5,000 418,000.00 SEK
2023-05-16 Gunilla Osswald Other Buy 9,730 3,001,023.90 SEK

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.